New lung cancer drug shows promise in Early-Stage trial

NCT ID NCT07489066

Not yet recruiting Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Mar 30, 2026 · Last updated May 15, 2026 · Updated 5 times

Summary

This study tests a new medicine, PF-08634404, given alone or with chemotherapy for adults with early or locally advanced non-small cell lung cancer. The goal is to see if it can shrink tumors before surgery or prevent cancer from returning after treatment. About 120 participants will be enrolled across three groups based on their specific cancer stage and treatment history.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.